• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

长期促性腺激素释放激素类似物治疗对前列腺癌患者激素水平及精子发生的影响。

Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate.

作者信息

Lunglmayr G, Girsch E, Meixner E M, Viehberger G, Bieglmayer C

机构信息

Department of Urology, Mistelbach General Infirmary, Austria.

出版信息

Urol Res. 1988;16(4):315-9. doi: 10.1007/BF00263642.

DOI:10.1007/BF00263642
PMID:2972102
Abstract

The effects of long term GnRH treatment with the biodegradable depot formulation of ICI 118.630 on hormone levels and spermatogenesis were investigated in 18 males with advanced prostate cancer. Plasma levels of FSH, LH, testosterone, DHEA-S and SHBG were monitored at regular intervals. The drug suppressed FSH, LH and testosterone significantly and did not affect DHEA-S and SHBG plasma levels. Tissue specimens for histologic assessment and quantitative analysis of germinal cell types were obtained at secondary orchidectomy in 16 patients immediately following GnRH analogue treatment. Germinal cell maturation was arrested at the spermatogonial stage. In two patients discontinuing treatment histologic assessment of secondary orchidectomy specimens 9 and 10 months after the last GnRH analogue depot injection resulted in germinal cell maturation to late spermatids in part of the tubule cross sections. These results indicate that long term administration of the GnRH analogue fails to produce complete testicular sclerosis and spermatogenic arrest might be reversible.

摘要

在18例晚期前列腺癌男性患者中,研究了使用可生物降解长效剂型的ICI 118.630长期进行促性腺激素释放激素(GnRH)治疗对激素水平和精子发生的影响。定期监测促卵泡生成素(FSH)、促黄体生成素(LH)、睾酮、硫酸脱氢表雄酮(DHEA-S)和性激素结合球蛋白(SHBG)的血浆水平。该药物显著抑制FSH、LH和睾酮,且不影响DHEA-S和SHBG的血浆水平。在16例患者接受GnRH类似物治疗后立即进行二次睾丸切除时,获取组织标本用于组织学评估和生殖细胞类型的定量分析。生殖细胞成熟停滞在精原细胞阶段。在2例停止治疗的患者中,末次GnRH类似物长效注射后9个月和10个月进行二次睾丸切除标本的组织学评估,结果显示部分小管横切面中的生殖细胞成熟至晚期精子细胞。这些结果表明,长期给予GnRH类似物不会导致完全的睾丸硬化,精子发生停滞可能是可逆的。

相似文献

1
Effects of long term GnRH analogue treatment on hormone levels and spermatogenesis in patients with carcinoma of the prostate.长期促性腺激素释放激素类似物治疗对前列腺癌患者激素水平及精子发生的影响。
Urol Res. 1988;16(4):315-9. doi: 10.1007/BF00263642.
2
Protection of spermatogenesis in rats from the cytotoxic procarbazine by the depot formulation of Zoladex, a gonadotropin-releasing hormone agonist.促性腺激素释放激素激动剂诺雷德长效制剂对大鼠精子发生的保护作用,使其免受细胞毒性药物丙卡巴肼的影响。
Cancer Res. 1990 Feb 1;50(3):568-74.
3
Testicular histology after treatment with LH-RH analogue for carcinoma of the prostate.用促黄体生成激素释放激素类似物治疗前列腺癌后的睾丸组织学。
Br J Urol. 1990 Apr;65(4):376-8. doi: 10.1111/j.1464-410x.1990.tb14759.x.
4
[Clinical effect of slow release (depot) formulation of the LH-RH analogue ICI 118630 (Zoladex) in patients with prostatic carcinoma].[促黄体生成素释放激素类似物ICI 118630(诺雷德)缓释(长效)制剂对前列腺癌患者的临床疗效]
Hinyokika Kiyo. 1987 Jan;33(1):141-50.
5
An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.一种促黄体生成素释放激素类似物(戈舍瑞林)用于前列腺癌治疗:每日皮下注射与每月长效注射的初步比较报告
Eur J Surg Oncol. 1985 Jun;11(2):159-65.
6
Depot gonadotropin-releasing hormone agonist blunts the androgen-induced suppression of spermatogenesis in a clinical trial of male contraception.在一项男性避孕临床试验中,长效促性腺激素释放激素激动剂可减弱雄激素诱导的精子发生抑制作用。
J Clin Endocrinol Metab. 1992 Jan;74(1):84-90. doi: 10.1210/jcem.74.1.1727833.
7
Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).使用促黄体生成激素释放激素(LHRH)激动剂ICI 118630(诺雷德)的缓释(长效)制剂治疗晚期前列腺癌患者。
J Endocrinol. 1984 Nov;103(2):R1-4. doi: 10.1677/joe.0.103r001.
8
Long-term therapy with a depot luteinizing hormone-releasing hormone analogue (Zoladex) in patients with advanced prostatic carcinoma.长效促黄体生成素释放激素类似物(诺雷德)用于晚期前列腺癌患者的长期治疗。
J Urol. 1988 Oct;140(4):775-7. doi: 10.1016/s0022-5347(17)41809-x.
9
[Treatment of advanced prostatic carcinoma with a depot LH-RH analog (ICI 118630)].用长效促黄体生成素释放激素类似物(ICI 118630)治疗晚期前列腺癌
Minerva Urol Nefrol. 1989 Jan-Mar;41(1):5-10.
10
Preliminary report on use of depot formulation of LHRH analogue ICI 118630 (Zoladex) in patients with prostatic cancer.促黄体生成素释放激素类似物ICI 118630(诺雷德)长效制剂用于前列腺癌患者的初步报告。
Br Med J (Clin Res Ed). 1985 Jan 19;290(6463):185-7. doi: 10.1136/bmj.290.6463.185.

引用本文的文献

1
Fertility preservation options in transgender people: A review.跨性别者的生育力保存选择:综述。
Rev Endocr Metab Disord. 2018 Sep;19(3):231-242. doi: 10.1007/s11154-018-9462-3.
2
Controversies in the management of advanced prostate cancer.晚期前列腺癌治疗中的争议
Br J Cancer. 1999 Jan;79(1):146-55. doi: 10.1038/sj.bjc.6690024.
3
Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer.戈舍瑞林。其药效学和药代动力学特性以及在前列腺癌治疗中的疗效综述。

本文引用的文献

1
The testis, breast and prostate of men who die of cirrhosis of the liver.死于肝硬化的男性的睾丸、乳房和前列腺。
Am J Clin Pathol. 1950 Sep;20(9):814-28. doi: 10.1093/ajcp/20.9.814.
2
RAPID TOLUIDINE BLUE STAINING OF EPON-EMBEDDED AND MOUNTED "ADJACENT" SECTIONS.对环氧树脂包埋并固定的“相邻”切片进行快速甲苯胺蓝染色。
Am J Clin Pathol. 1965 Jul;44:57-8. doi: 10.1093/ajcp/44.1.57.
3
The cycle of the seminiferous epithelium in man.男性生精上皮的周期
Drugs Aging. 1995 Apr;6(4):324-43. doi: 10.2165/00002512-199506040-00007.
Am J Anat. 1963 Jan;112:35-51. doi: 10.1002/aja.1001120103.
4
Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.成年男性长期经鼻内和皮下给予强效促黄体生成激素释放激素(LH-RH)激动剂对血清雄激素水平的抑制作用。
Fertil Steril. 1982 Mar;37(3):416-24. doi: 10.1016/s0015-0282(16)46107-8.
5
Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists.用促黄体生成素释放激素激动剂治疗的前列腺癌患者的肿瘤生长抑制
Proc Natl Acad Sci U S A. 1982 Mar;79(5):1658-62. doi: 10.1073/pnas.79.5.1658.
6
Testicular histology following chronic gonadotropin-releasing hormone agonist treatment.
Fertil Steril. 1984 Nov;42(5):765-71. doi: 10.1016/s0015-0282(16)48205-1.
7
Androgen suppression by a gonadotropin releasing hormone analogue in patients with metastatic carcinoma of the prostate.
J Urol. 1984 Jun;131(6):1110-2. doi: 10.1016/s0022-5347(17)50833-2.
8
A comparison of a powerful luteinizing hormone releasing hormone analogue agonist and estrogen in the treatment of advanced prostatic cancer.
J Urol. 1984 Jun;131(6):1107-9. doi: 10.1016/s0022-5347(17)50832-0.
9
Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).使用促黄体生成激素释放激素(LHRH)激动剂ICI 118630(诺雷德)的缓释(长效)制剂治疗晚期前列腺癌患者。
J Endocrinol. 1984 Nov;103(2):R1-4. doi: 10.1677/joe.0.103r001.
10
The restoration of human spermatogenesis and of the reproductive tract with urinary gonadotropins following hypophysectomy.垂体切除术后使用尿促性腺激素恢复人类精子发生及生殖道功能。
Fertil Steril. 1966 Jan-Feb;17(1):7-23. doi: 10.1016/s0015-0282(16)35821-6.